Amanta Healthcare Ltd

AGM notice and annual report access

• 31st AGM scheduled for 16 September 2026 at 12:00 IST via VC/OAVM.
• Integrated Annual Report for FY2025-26 and AGM notice accessible online.
• Weblink path: https://www.amanta.co.in/annual-report.
• Shareholders without registered email addresses by Aug 14, 2026 advised to update details.
• SEBI LODR-based KYC updation and dematerialisation of physical securities highlighted.
• RTA helpdesk link provided for electronic service requests.
• Physical-holding payments will be through electronic mode only from Apr 1, 2024.
• Letter dated Aug 24, 2026 informing non-registered email holders.
• Company Secretary and Compliance Officer: Nikhita Dinodia.

Financials

• Revenue from operations: ₹28,767.67 Lakhs; up 5% YoY.
• EBITDA: ₹6,322.92 Lakhs; margin 22%.
• PAT: ₹1,487.52 Lakhs; margin 5%.
• EPS: ₹4.33 (basic and diluted).
• ROE 8.94%; ROCE 11.11%.
• Debt-to-Equity 0.99x; DSCR 1.01x.

Debt & capital structure

• Total borrowings: ₹24,444.34 Lakhs; equity: ₹3,882.94 Lakhs.
• IPO proceeds raised: ₹126 Crores; anchor allocations ₹37.80 Crores.
• Debt-to-Equity declined from 3x+ in FY23 to 0.99x in FY26.

Capex & capacity expansion

• SteriPort capacity to ~12 crore bottles/year (from 6.6).
• SVP capacity to ~31.7 crore units by FY27.
• FY26 capex: ₹130 Crores for SteriPort; ₹25 Crores for SVP.
• 8 MW captive solar plant commissioned; ₹9 Crores annual savings from FY27.

IPO proceeds & usage

• IPO proceeds: ₹126 Crores; used for capex and general corporate purposes.
• Unutilised IPO proceeds: ₹5,246.75 Lakhs as of 31 Mar 2026.
• Monitoring of utilisation by CRISIL; annual quarterly reviews.

Geography & product footprint

• Domestic revenue ₹17,349.76 Lakhs; export ₹11,069.63 Lakhs (FY26).
• Export markets: 20 countries; 47 products registered across 120 jurisdictions.
• Six therapeutic segments; LVP and SVP capabilities with ISBM/ABFS.

ESG, sustainability & CSR

• ISO 14001:2015; WHO-GMP; captive solar plant reduces carbon footprint.
• CSR spend ₹28.72 Lakhs; CSR obligation ₹14.99 Lakhs; no shortfall.
• ESG initiatives include greener packaging, energy efficiency, and water reuse.

Governance & risk

• Board: 6 directors; 3 independent; 1 woman. Audit Committee reconstituted.
• Secretarial Auditor: Kashyap R. Mehta & Partners; 5-year term subject to AGM approval.
• Statutory Auditor: PwC; 5-year term; unmodified opinion.
• Dividend: no dividend declared for FY26.

Key business risks

• Foreign exchange risk in 20 export markets; hedging limited.
• Single manufacturing site; potential supply/disruption risk.
• Pricing pressure in competitive segments; shift to differentiated products.

Financial Performance

• Q1 FY27 revenue INR 69 crores, up 5% YoY; EBITDA margin ~22%.
• SteriPort accounts for about 44% of revenue; high-margin product mix supporting profitability.
• QB: EBITDA INR 15 crores; EBITDA margin remained about 22%.

Operational Update

• SteriPort Line 3 commissioning shifted to Q2 FY27 due to civil delays.
• Capacity rises from 6.6 crore to about 12 crore bottles annually.
• SVP facility to commence operations in Q4 FY27; first inhalation product mid-September FY27.
• FDA-approved plans; validation complete by Aug 18; commercial production by last week of August.

Capex and Projects

• SteriPort Line 3 capex ~ INR 90 crores; ~INR 80 crores spent so far.
• SVP capex ~ INR 30 crores; ~INR 7 crores spent; remainder in coming quarters.
• Solar power: 10.8 MW captive plant commissioned since June 2026; expected to cut power costs.

Guidance and Outlook

• Margin expansion target 4-5% including INR 9 crores solar savings.
• FY27 baseline revenue around INR 370 crores; SteriPort contributes ~INR 70 crores over seven months.
• FY28 peak revenue ~ INR 425 crores; EBITDA margins ~ 25-26%.
• SteriPort Line 3 operational by Aug 24-25, 2026; SVP by March FY27.

Balance Sheet and Cash Flow

• Debt-to-equity at 1.06; annual debt reduction expected at INR 30-35 crores.
• Interest expense trending down; FY27 ~ INR 21 crores; FY28 ~ INR 19 crores.

Q&A Highlights

• Line 3 annual top-line expected INR 120 crores; seven months contributed ~INR 70 crores.
• Depreciation from new line ~ INR 4.5 crores annually; total incremental ~ INR 6 crores.
• ROCE: SteriPort line ~16-17%; SVP ~14-15%.
• FAT in USA scheduled for November; SVP pipeline includes 20 products; inhalation product commercialized mid-September FY27.
• R&D: 5 scientists in F&D; 8-10 F&D and 3-4 regulatory staff for advanced markets.

Issue Overview

• IPO of equity shares; net proceeds revised downward due to higher expenses.
• Objectives: fund capex for SteriPort and SVP lines, plus general corporate purposes.

Utilisation of Proceeds

• Utilisation aligned with offer document.
• No material deviations observed; allocation unchanged.
• SteriPort: partial utilisation; end-quarter progress shows ongoing use in capex.
• SVP: partial utilisation; some funds remain unutilised.
• GCP: fully utilised; no unutilised funds remaining.
• Unutilised proceeds held in fixed deposits and monitoring accounts; some funds encumbered.
• Total unutilised balance noted, across objects.

Governance and Compliance

• Approvals: statutory approvals for objects NA; no shareholder approvals needed.
• Delay in implementation noted; due to supplier payments and finalization of terms.
• Vendor arrangements modified relative to prospectus; changes within disclosures.

General Corporate Purpose (GCP)

• GCP utilised; amount allocated for GCP used; fully used.
• Board approval for allocation not explicitly stated in MA.

Meeting Details

• Date: August 6, 2026
• Time: not disclosed
• Type/Mode: group conference call; virtual
• Event: Post Results Conference Call

Purpose

• Post-results discussion; recording of call hosted on company site

Additional Notes

• Audio recording available on the company's investor-meet page

Key financials and expansion

• Q1FY27 revenue ₹68.80 crore, up 5.4% YoY.
• EBITDA ₹15.18 crore; margin 22% (vs 24% prior).
• PAT ₹3.31 crore; PAT margin 4.8% (vs 5.3%).
• Profitability affected by higher finance costs from Solar Term Loan.
• SteriPort facility to be commissioned by Q2FY27.
• SVP expansion targeted for Q4FY27 to boost capacity.
• Captive solar power project to support cost efficiency.
• Capacity expansion to create headroom for growth in domestic and export markets.

IPO funds utilization

• No deviation or variation in use of IPO funds for quarter ended June 30, 2026.
• Funds raised: ₹126 crore from IPO on September 9, 2025, monitored by CRISIL Ratings Limited.
• Monitoring agency: CRISIL Ratings Limited, applicable to the IPO funds.
• Original allocations include funding for SteriPort and SVP manufacturing lines at Hariyala, Gujarat.
• General corporate purposes allocated ₹660.46 lakhs, later modified to ₹302.08 lakhs.
• Issue expenses increased to ₹2,284.81 lakhs due to GST adjustment.
• Funds utilised for civil capex and equipment remains as per original allocations with no material deviation.
• Audit Committee reviews: no comments reported.